Antibody engineering and its therapeutic applications

Kandari, Divya; Bhatnagar, Rakesh

doi:10.1080/08830185.2021.1960986

Cited by 10 publications

(4 citation statements)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, the generation of antibody fragments, specifically Fab and (Fab)2 0 , relied on proteolytic cleavage of classical antibodies. 46,48,49 However, Plückthun and Skerra have outlined an alternative approach using cloning vectors to produce fully functional Fv and Fab fragments. By employing cloning vectors, antibodies can be directed into the periplasmic space, benefitting from the oxidizing environment that facilitates disulfide bond formation.…”

Section: Discussionmentioning

confidence: 99%

“…Bioengineered antibodies exhibit characteristics such as low molecular mass, high physicochemical stability, increased flexibility, and easy accessibility to antigens, making them potential substitutes that emulate naturally generated antibodies. Previously, the generation of antibody fragments, specifically Fab and (Fab)2′, relied on proteolytic cleavage of classical antibodies 46,48,49 . However, Plückthun and Skerra have outlined an alternative approach using cloning vectors to produce fully functional Fv and Fab fragments.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Utilizing fab fragment‐conjugated surface plasmon resonance‐based biosensor for detection of SalmonellaEnteritidis

Eser,

Ekiz,

Ekiz

2024

J of Molecular Recognition

View full text Add to dashboard Cite

Although antibodies, a key element of biorecognition, are frequently used as biosensor probes, the use of these large molecules can lead to adverse effects. Fab fragments can be reduced to allow proper antigen‐binding orientation via thiol groups containing Fab sites that can directly penetrate Au sites chemically. In this study, the ability of the surface plasmon resonance (SPR) sensor to detect Salmonella was studied. Tris(2‐carboxyethyl)phosphine was used as a reducing agent to obtain half antibody fragments. Sensor surface was immobilized with antibody, and bacteria suspensions were injected from low to high concentrations. Response units were changed by binding first reduced antibody fragments, then bacteria. The biosensor was able to determine the bacterial concentrations between 103 and 108 CFU/mL. Based on these results, the half antibody fragmentation method can be generalized for faster, label‐free, sensitive, and selective detection of other bacteria species.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Utilizing fab fragment‐conjugated surface plasmon resonance‐based biosensor for detection of SalmonellaEnteritidis

Eser,

Ekiz,

Ekiz

2024

J of Molecular Recognition

View full text Add to dashboard Cite

show abstract

“…Targeted therapy and diagnostic imaging can be carried out on a flexible platform so that these proteins can be arranged to bind preferentially to cancerassociated indicators. Relative to conventional antibodies, engineered proteins provide the benefit of lower immunogenicity [10]. However, since they can be expensive and hard to produce, additional optimization is required to make the manufacturing process more efficient.…”

Section: Multistep Glycosylation Proteins Targeting Agentsmentioning

confidence: 99%

Immunotherapy Influence On Human Body: Glycan Engineering Antibody-Based Cancer Treatments

2024

J COMM MED PUB HEALTH REP

View full text Add to dashboard Cite

Analysis of cells, soluble substances, and related tissues and cells that cooperate to extend life continues to awaken researchers' curiosity.Because of its incredible complexity, the immune system is opaque to the outer world. Scholars strive to comprehend the several facets that combine to give a comprehensive picture of the system's operation. Thus, various tactics have been acknowledged for their role in the development of immunotherapy, including genetic approaches, animal models, specialized tools, monoclonal antibodies, and immunological techniques. Much research has been done to understand the effects of immunotherapy on human bodies to develop a range of treatments.Understanding the various aspects of immunotherapy's role in health, sickness management, and aging has been made possible by the discoveries about cell subsets, membrane molecules, and cell functions. A thorough grasp of the systems and elements that provide an enabling platform for welfare management has resulted from a focus on the aspects of immunotherapy. Welfare management falls under the purview of developing various immunotherapies, which have served as the cornerstone for sustainable welfare management. The impact of the application of immunotherapy has been explored in the context of efficient service delivery, ranging from cancer to tumor management. The effect on human bodies has been clarified by developing several immunotherapies, such as adopting infections, adopting them prophylactically, and using monoclonal antibodies and recombinant proteins. Investing in immunotherapy has, therefore, been responsible for the change in how we treat many diseases. The necessity to investigate immunotherapy and its impact on human bodies has led to the development of an enabling platform for examining and adequately managing diseases.

show abstract

“…Production of humanized and fully human antibodies has been evolved tremendously for medical purposes to reduce the immunogenicity of the non-human isotype [ 27 ]. Moreover, the intact four chain-mAb molecule has demonstrated clinical disadvantages, such as poor tissue penetration and slow blood clearance due to the large size (~150 kDa), and particularly induced proinflammatory responses due to the presence of the Fc portion, which can interact and activate effector cells and the complement cascade [ 27 , 28 ]. Thus, Ab engineering has been investigated to reduce the immunogenicity of Ab for medical use.…”

Section: Introductionmentioning

confidence: 99%

Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention

et al. 2022

View full text Add to dashboard Cite

Percutaneous coronary intervention (PCI) is a common procedure for the management of coronary artery obstruction. However, it usually causes vascular wall injury leading to restenosis that limits the long-term success of the PCI endeavor. The ultimate objective of this study was to develop the targeting nanoparticles (NPs) that were destined for the injured subendothelium and attract endothelial progenitor cells (EPCs) to the damaged location for endothelium regeneration. Biodegradable poly(lactic-co-glycolic acid) (PLGA) NPs were conjugated with double targeting moieties, which are glycoprotein Ib alpha chain (GPIbα) and human single-chain antibody variable fragment (HuscFv) specific to the cluster of differentiation 34 (CD34). GPIb is a platelet receptor that interacts with the von Willebrand factor (vWF), highly deposited on the damaged subendothelial surface, while CD34 is a surface marker of EPCs. A candidate anti-CD34 HuscFv was successfully constructed using a phage display biopanning technique. The HuscFv could be purified and showed binding affinity to the CD34-positive cells. The GPIb-conjugated NPs (GPIb-NPs) could target vWF and prevent platelet adherence to vWF in vitro. Furthermore, the HuscFv-conjugated NPs (HuscFv-NPs) could capture CD34-positive cells. The bispecific NPs have high potential to locate at the damaged subendothelial surface and capture EPCs for accelerating the vessel repair.

show abstract

Antibody engineering and its therapeutic applications

Cited by 10 publications

References 166 publications

Utilizing fab fragment‐conjugated surface plasmon resonance‐based biosensor for detection of SalmonellaEnteritidis

Utilizing fab fragment‐conjugated surface plasmon resonance‐based biosensor for detection of SalmonellaEnteritidis

Immunotherapy Influence On Human Body: Glycan Engineering Antibody-Based Cancer Treatments

Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention

Contact Info

Product

Resources

About